Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry. J of Skin [Internet]. 2017 Oct. 27 [cited 2025 Apr. 19];1(3.1):s22. Available from: https://skin.dermsquared.com/skin/article/view/79